Vitestro Raises $70 Million Series B to Advance Autonomous Robotic Blood Collection

Vitestro has secured $70 million in an oversubscribed Series B financing round to advance the development and commercialization of its autonomous robotic blood collection technology. The Utrecht, Netherlands-based medical robotics company said the proceeds will support development of the next-generation Aletta system and expand its integration into high-volume clinical workflows. The funding will also support the company’s De Novo regulatory pathway with the U.S. Food and Drug Administration and prepare for broader market entry, beginning in Europe and later targeting the U.S. market.

Vitestro’s Aletta® ARPD™ system is designed to autonomously perform diagnostic blood collection by combining multimodal imaging, robotics, and artificial intelligence. The platform is intended to identify suitable veins, guide needle insertion, and collect blood samples while supporting routine diagnostic blood draw procedures in high-volume outpatient care settings.

The financing round included new strategic investment from Labcorp Venture Fund, Mayo Clinic, and Sutter Health, alongside financial investors InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht. Existing investors Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital also participated.

“Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection,” said Toon Overbeeke, Chief Executive Officer and co-founder of Vitestro. “Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this distinguished syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption. Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of procedures performed annually.”